Nonalcoholic fatty liver disease (
NAFLD) is commonly associated with
obesity. This randomized, double-blind, placebo-controlled trial aimed to evaluate the effects of turmeric on serum
adiponectin and
sirtuin 1 (
SIRT1) levels, blood pressure, and body mass index (BMI) in patients with
NAFLD. A total of 46 eligible patients with
NAFLD (BMI, 25.0∼39.9 kg/m2) were randomly allocated to turmeric and placebo groups using block randomization. The turmeric group (n=23) was administered 3,000 mg/d turmeric
powder in six 500-mg capsules for 12 weeks, whereas the placebo group (n=23) was administered six placebo capsules/d for 12 weeks.
Body weight, BMI, serum
SIRT1 and
adiponectin levels, and systolic and diastolic blood pressures were measured at baseline and 12 weeks after intervention. Serum
SIRT1 levels increased significantly in the turmeric group compared with the placebo group. Additionally, participants in the turmeric group exhibited lower weight, BMI, and systolic blood pressure after 12 weeks of intervention compared with the baseline. Turmeric effectively improved
SIRT1 levels in patients with
NAFLD compared with the placebo. The efficacy of turmeric might increase with long-term use at higher doses.